Prof Niall Tebbutt
Clinical (Professor)
Department of Surgery
452 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature
DOI: 10.1016/j.xcrm.2026.1026942026
Journal article
Abstract CT094: A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer
DOI: 10.1158/1538-7445.am2026-ct0942026
Journal article
Abstract CT183: Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer
DOI: 10.1158/1538-7445.am2026-ct1832026
Journal article
From chemotherapy to molecular targeted therapy in advanced biliary tract cancer
DOI: 10.20935/acadonco81712026
Journal article
Zanidatamab chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2 ) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.
DOI: 10.1200/jco.2026.44.2_suppl.lba2852026
Journal article
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective
DOI: 10.1016/j.clcc.2026.04.0012017
Research Grant
Mapping Patterns of Care for People With Pancreatic Cancer: How Close Are We to the Optimal Care Pathway Recommendations?
RECENT SCHOLARLY WORKS
2026
Journal article
MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice—A Narrative Review
DOI: 10.3390/curroncol330100342025
Journal article
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
DOI: 10.1038/s41591-025-04030-w2025
Journal article
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines
DOI: 10.1038/s42003-025-08251-02025
Other
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
DOI: 10.1158/1078-0432.30707564